IMPACT-DCM 2014

NCT00765518

1 Treatments

**Studied treatment**  ixmyelocel-T: an expanded, autologous multi-cellular therapy, ixmyelocel-T was administered intramyocardially via minithoracotomy

**Control treatment**

**Concomittant treatments**

**cell type**

**Cell injection procedure**

2 Patients

**Patients**  patients with dilated cardiomyopathy

**Inclusion criteria**

**Exclusion criteria**

3 Methods

**Blinding**

**Design**

**Centers**

**Geographical area**

**Sizes**  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>acute heart failure</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>ventricular tachycardia</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>NYHA deterioration</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiac event</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all-cause mortality</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References